Last A$22.39 AUD
Change Today +0.08 / 0.36%
Volume 247.5K
SRX On Other Exchanges
As of 2:10 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

sirtex medical ltd (SRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - A$23.34
52 Week Low
12/10/13 - A$10.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIRTEX MEDICAL LTD (SRX)

Related News

No related news articles were found.

sirtex medical ltd (SRX) Related Businessweek News

No Related Businessweek News Found

sirtex medical ltd (SRX) Details

Sirtex Medical Limited, a life-sciences company, develops and distributes oncology treatments using small particle technology in the Asia Pacific, the Americas, Europe, the Middle East, and Africa. The company provides SIR-Spheres microspheres, a medical device used in interventional oncology to deliver selective internal radiation therapy to the liver. It has a collaboration agreement with Guerbet to examine ways SIR-Spheres microspheres can be combined with its imaging agent Lipiodol to address the unmet clinical needs in patients with hepatocellular carcinoma, metastatic colorectal cancer, and metastatic neuroendocrine tumours. The company is based in North Sydney, Australia.

213 Employees
Last Reported Date: 08/19/14

sirtex medical ltd (SRX) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$998.5K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$468.3K
Global Head of Operations
Total Annual Compensation: A$462.0K
Chief Executive Officer of Europe
Total Annual Compensation: A$698.1K
Chief Executive Officer of Asia Pacific Regio...
Total Annual Compensation: A$456.4K
Compensation as of Fiscal Year 2014.

sirtex medical ltd (SRX) Key Developments

Sirtex Medical Limited Declares Fully Franked Ordinary Dividend

Sirtex Medical Limited has declared fully franked ordinary dividend of 12 cents (2013: 10 cents) per share franked at the tax rate of 30% (2013: 30%).

Sirtex Medical Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Sirtex Medical Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue from the sale of goods was $129,363,000 compared to $96,774,000 a year ago. Profit before tax was $31,110,000 compared to $24,507,000 a year ago. Profit for the year was $23,868,000 compared to $18,270,000 a year ago Diluted earnings per share were 41.3 cents compared to 32 cents a year ago. Net cash provided by operating activities was $32,171,000 compared to $24,327,000 a year ago. Purchase of plant and equipment was $6,189,000 compared to $3,695,000 a year ago. Revenue from ordinary activities was $131,292,000 compared to $100,303,000 a year ago. Net Tangible asset backing per ordinary security was 107.3 cents compared to 107.3 cents a year ago.

Sirtex Medical Limited, 2014 Earnings Call, Aug 20, 2014

Sirtex Medical Limited, 2014 Earnings Call, Aug 20, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRX:AU A$22.39 AUD +0.08

SRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $13.29 USD -0.60
Delcath Systems Inc $2.18 USD -0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation SRX Industry Range
Price/Earnings 51.3x
Price/Sales 9.2x
Price/Book 11.1x
Price/Cash Flow 50.2x
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRTEX MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at